Publications 2010

1 Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. V Soriano, A Mocroft, L Peters, J Rockstroh, F Antunes, N Kirkby, S de Wit, A d'Arminio Monforte, Robert Flisiak and J Lundgren on behalf of EuroSIDA
J Antimocrob Chemother. 2010 Mar;65(3):548-55. PubMed PMID: 20051475.

2 History of viral suppression on cART as a predictor of virological failure after a treatment change. J Reekie, A Mocroft, B Ledergerber, M Beniowski, B Clotet, J van Lunzen, A Chiesi, C Pradier, L Machala, J D Lundgren on behalf of the EuroSIDA Study Group.
HIV Medicine. 2010 Aug;11(7):469-78. Epub 2010 Feb 22. Pubmed PMID: 20201975.

3 Markers of inflammation, coagulation and renal function are elevated in adults with HIV infection.  J Neuhaus, DR Jacobs Jr., JV Baker, A Calmy, D Duprez, A La Rosa, LH Kuller, SL Pett, M Ristola, MJ Ross, MG Shlipak, R Tracy, JD Neaton for the INSIGHT SMART, MESA and CARDIA Research Groups
J Infect Dis 2010; 201(12):1788-1795.

4 Risk of all-cause mortality associated with non-fatal AIDS and serious non-AIDS events among adults infected with HIV. J Neuhaus, B Angus, J Kowalska, A La Rosa, J Sampson, D Wentworth, A Mocroft; for the INSIGHT SMART and ESPRIT Study Groups.
AIDS. 2010 March 1324(5):697-706. PubMed PMID: 20177360. article

5 Relationship between current level of immunodeficiency and non-AIDS defining malignancies. J Reekie, C Kosa, F Engsig, A d'Arminio Monforte, A Wiercinska-Drapalo, P Domingo, F Antunes, N Clumeck, O Kirk, JD Lundgren, A Mocroft for the EuroSIDA study group.
Cancer. 2010 Nov15;116(22):5306-15. PubMed PMID: 20661911. abstract

6 Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years.The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
Arch Intern Med 2010, 170:410-419. PubMed PMID: 20212176. article

7 Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. A Mocroft, O Kirk, P Reiss, S De Wit, D Sedlacek, M Beniowski, J Gatell, AN Phillips, B Ledergerber, JD Lundgren, for the EuroSIDA Study Group.
AIDS. 2010 Jul 17;24(11):1667-78. PubMed PMID: 20523203. abstract

8 Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. The Antiretroviral Therapy Cohort Collaboration Study Group (ART-CC).
Clin Infect Dis. 2010 May 15;50(10):1387-96. PubMed PMID:20380565. abstract

9 High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. SW Worm, N Friis-Møller, M Bruyand, A D'Arminio Monforte, M Rickenbach, P Reiss, W El-Sadr, A Phillips, J Lundgren, C Sabin, for the DAD study group.
AIDS. 2010 Jan 28;24(3):427-35. PubMed PMID: 19910787. article

10 Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Worm SW, Sabin S, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Fontas E, Weller I, Phillips a, Lundgren J.
J Infect Dis. 2010 Feb 1;201(3):318-30. PubMed PMID: 20039804. article

11 Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HV infection and a CD4 cell count <200 cells/mL? The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE).
Clinical Infectious Diseases. 2010;51(5):611-19. PubMed PMID: 20645862. article

12 Estimated average annual rate of change of CD4 counts in patients on combination antiretroviral therapy. A Mocroft, AN Phillips, B Ledergerber, C Smith, JR Bogner, K Lacombe, A Wiercinska-Drapalo, P Reiss, O Kirk, JD Lundgren for the EuroSIDA study group.
Antiviral Therapy 2010. 15:563-570. PubMed PMID: 20587849. article

13 Predicting the risk of cardiovascular disease in HIV-infected patients: the Data Collection on Adverse Effects of Anti-HIV Drugs Study. N Friis-Møller, R Thiébaut, P Reiss, R Weber, AD Monforte, S De Wit, W El-Sadr, E Fontas, S Worm, O Kirk, A Phillips, C Sabin, JD Lundgren, M Law; for the DAD study group.
Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501. PubMed PMID: 20543702. article

14 Overcoming obstacles to late presentation for HIV infection in Europe. JV Lazarus, R Jürgens, M Weait, A Phillips, J Hows, J Gatell, T Coenen, A Sönnerborg, D Raben and JD Lundgren.
HIV Medicine. 2010 Aug 29. PubMed PMID: 20807253. article

15 Notification of suspected and unexpected serious adverse reactions according to the Clinical Trials Directive - A descriptive analysis of the legislation and the requirements in a European context. EM Larsen, J Grarup, DC Gey, KB Jensen, O Kirk.
Clinical Research and Regulatory Affairs Dec 2010, Vol. 27, No. 4:108–120 article

16 Dialysis and Renal Transplantation in HIV-Infected Patients: a European Survey. JC Trullas, A Mocroft, F Cofan, J Tourret, A Moreno, CI Bagnis, CA Fux, C Katlama, P Reiss, J Lundgren, JM Gatell, O Kirk, JM Miró; the EuroSIDA Investigators.
J Acquir Immune Defic Syndr. 2010 Aug 31. [Epub ahead of print] PubMed PMID: 20811290.

17 Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. GJ Dore, V Soriano, J Rockstroh, B Kupfer, E Tedaldi, L Peters, J Neuhaus, M Puoti, MB Klein, A Mocroft, B Clotet, JD Lundgren for the SMART INSIGHT study group.
AIDS 2010; 24:857-865.Pub Med PMID: 20216301.

19 Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. Achhra A, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, Vjecha MJ, Neaton JD, Cooper DA for INSIGHT ESPRIT & SILCAAT study groups.
AIDS 2010; 24(12):1877-1886. PubMed PMID: 20588170. article

20 Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. Tavel JA, INSIGHT STALWART Study Group.
PLoS One 2010; 5(2): e9334. doi:10.1371/journal.pone.0009334. PubMed PMID: 20186278. article

21 Smoking-related risk of all-cause mortality and serious clinical events among HIV-infected patients receiving highly active antiretroviral therapy in the Strategies for Management of Antiretroviral Therapy clinical trial. Lifson AR, Neuhaus J, Arribas JR, van den Bergwolf M, Labriola MN, Read TRH for the INSIGHT SMART study group.
Am J Pub Health 2010; Aug 19, 2010, epub ahead of print. PubMed PMID: 20724677. article

22 The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. Martinez E, Visnegarwala F, Grund B, Thomas A, Gibert C, Shlay J, Drummond F, Pearce D, Edwards S, Reiss P, El-Sadr W, Carr A for the INSIGHT SMART study group.
AIDS 2010; 24:353-363. PubMed PMID: 20057309. article

23 Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study group. C Smith, SW Worm, N Friis-Møller, CA Sabin, A Sjøl, JD Lundrgen, R Salbøl-Brandt, M Rickenbach, P Pezzotti, E Krum, L Gras, E Balestre, A Sundström, M Delforge, E Fontas, F Torres, K Petoumenos, J Kjær, S Collins, S Storpher, G Pearce, R Rode, I Weller.
AIDS. 2010 Jun 19;24(10):1537-48.

24 HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. R Weber, C Sabin, P Reiss, S de Wit, SW Worm, M Law, F Dabis, A d'Arminio Monforte, E Fontas, W El-Sadr, O Kirk, M Rickenbach, A Phillips, B Ledergerber, J Lundgren.
Antivir Ther. 2010;15(8):1077-86.

25 Rescue of severely immunocompromised HIV-positive persons. JD Lundgren, AN Phillips.
J Infect Dis. 2010 Nov 15;202(10):1467-9. [Editorial Commentary on: J Infect Dis. 2010 Nov 15;202(10):1529-37.]

26 Biomarkers in HIV Disease. JD Lundgren, J Baxter, SG Deeks, HC Lane.
Curr Opin HIV & AIDS. 2010 Nov;5(6):459-62.

27 Role of biomarkers in predicting CVD risk in the setting of HIV infection? SW Worm, P Hsue.
Curr Opin HIV & AIDS. 2010 Nov;5 (6):467-72.

28 Biomarkers of fibrosis and impaired liver function in chronic hepatitis C: how well do they predict clinical outcomes? L Peters, JK Rockstroh. Curr Opin HIV & AIDS. 2010 Nov;5(6):517-23.

29 Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health. JD Neaton, A Babiker, M Bohnhorst, J Darbyshire, E Denning, A Frishman, J Grarup, G Larson, J Lundgren. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Clin Trials. 2010 Dec;7(6):705-18.

30 Use of biomarker procalcitonin for diagnosis, prognosis, and treatment guidance in critically ill patients. ME Johansen, JU Jensen.
Klinisk Biokemi i Norden. 2010;4(22).

Updated: 02 Feb 2012